Trials
1 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IMP will be administered via IV infusion on 5 consecutive days”In the company’s words, NCT05722938 on ClinicalTrials.gov
- Tested for
- Community-acquired Pneumonia
- Main trialPhase 3
- “The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.”In the company’s words, NCT05722938 on ClinicalTrials.gov
- Other names
- BT588
Other drugs for Community-acquired Pneumonia
Coming up1
- 31 Jul 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Jul 2028 | Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) | |
| Phase 3Terminated | 5 May 2025 | Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia | |
| Phase 2Completed | 29 Jun 2021 | Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026